UPDATE: Gilead Press Release Regarding Phase 3 Harvoni Study By: Benzinga via Benzinga February 26, 2015 at 15:15 PM EST Gilead Sciences, Inc. (NASDAQ: GILD) today announced results from a Phase 3 study, ION-4, evaluating the once-daily single tablet ... Read More >> Related Stocks: Gilead Sciences